Atlas Trials

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Clinical trial NCT05292742 · RECRUITING

Trial details

NCT number
NCT05292742
Sponsor
Fujian Medical University Union Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerAdjuvant Therapy
Start date
2021-07-02
Primary completion
2026-10-01
Enrollment
206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.